Natural Product (NP) Details
| General Information of the NP (ID: NP3872) | |||||
|---|---|---|---|---|---|
| Name |
Paeonol
|
||||
| Synonyms |
PAEONOL; 552-41-0; 2'-Hydroxy-4'-methoxyacetophenone; 1-(2-Hydroxy-4-methoxyphenyl)ethanone; Peonol; 2-Hydroxy-4-methoxyacetophenone; Ethanone, 1-(2-hydroxy-4-methoxyphenyl)-; Resacetophenone-4-methyl ether; 1-(2-hydroxy-4-methoxyphenyl)ethan-1-one; MFCD00008730; Paeonal; Paeonolum; UNII-3R834EPI82; 4-Methoxy-2-hydroxyacetophenone; 4'-Methoxy-2'-hydroxyacetophenone; Acetophenone, 2'-hydroxy-4'-methoxy-; 1-(2-hydroxy-4-methoxy-phenyl)ethanone; CHEMBL1079227; CHEBI:69581; 3R834EPI82; 1-(2-hydroxy-4-methoxy-phenyl)-ethanone; 2'-Hydroxy-4'-methoxyacetophenone, 99%; 4-O-Methylresacetophenone; 1-acetyl-2-hydroxy-4-methoxybenzene; Resacetophenone, 4-O-methyl ester; EINECS 209-012-2; NSC 401442; BRN 1282794; 2-HYDROXY-4-METHOXYACETOPHENONE (4,4,4-D3); AI3-10581; Paeonol (Peonol); PubChem3271; ACMC-209lls; 1-[2-hydroxy-4-(methyloxy)phenyl]ethanone; Spectrum2_001981; Spectrum3_001686; 2-acetyl-5-methoxyphenol; 2-Acetyl-5-methoxy-phenol; CBiol_000986; BSPBio_003212; 4-08-00-01793 (Beilstein Handbook Reference); Acetophenone, 2'-hydroxy-4'-methoxy- (7CI,8CI); MLS006011902; SPECTRUM1601021; SPBio_002161; SCHEMBL1449478; ZINC1906; DTXSID1022059; KBio3_002432; 4-methoxy 2-hydroxy acetophenone; HMS3656E07; HMS3884J13; 2`-Hydroxy-4`-methoxyacetophenone; ACN-S003528; ACT07801; HY-N0159; ANW-32270; BBL012127; BDBM50310718; CCG-39471; CP0063; ICCB4_000282; NSC401442; s2339; SBB066134; STK078097; AKOS000119646; AC-7982; ACN-027221; AS05193; MCULE-2846207321; NSC-401442; SDCCGMLS-0066845.P001; 1-(2-hydroxy-4-methoxyphenyl)-ethanone; NCGC00095977-01; NCGC00095977-02; NCGC00095977-03; AK-79421; AS-15489; P565; SMR000112386; SY013508; 1-(2-Hydroxy-4-methoxyphenyl)ethanone #; 1-(4-Methoxy-2-hydroxy-phenyl)-ethanone; AB0044007; 1-(2-hydroxy-4-methoxyphenyl)ethane-1-one; AM20040702; FT-0602529; FT-0618875; N1847; ST45027685; SW219250-1; C10712; M-2917; 552H410; Ethanone, 1-(2-hydroxy-4-methoxyphenyl)- (9CI); SR-05000002397; Q-100626; Q7124105; SR-05000002397-1; BRD-K94239562-001-02-2; BRD-K94239562-001-03-0; 2 inverted exclamation mark -Hydroxy-4 inverted exclamation mark -methoxyacetophenone; 2 inverted exclamation marka-Hydroxy-4 inverted exclamation marka-methoxyacetophenone
Click to Show/Hide
|
||||
| Species Origin | Paeonia suffruticosa ... | Click to Show/Hide | |||
| Paeonia suffruticosa | |||||
| Disease | Lung cancer [ICD-11: 2C25] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.773
MDCK Permeability
-4.552
PAMPA
- - -
HIA
- - -
Distribution
VDss
-0.33
PPB
88.2%
BBB
- -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
+++
CYP2C19 inhibitor
+++
CYP2C19 substrate
- - -
CYP2C9 inhibitor
-
CYP2C9 substrate
- - -
CYP2D6 inhibitor
++
CYP2D6 substrate
+
CYP3A4 inhibitor
- -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
+++
Excretion
CLplasma
7.225
T1/2
1.247
Toxicity
DILI
-
Rat Oral Acute Toxicity
- -
FDAMDD
- -
Respiratory
++
Human Hepatotoxicity
-
Ototoxicity
- -
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
-
Hematotoxicity
-
Genotoxicity
- -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C9H10O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=O)C1=C(C=C(C=C1)OC)O
|
||||
| InChI |
1S/C9H10O3/c1-6(10)8-4-3-7(12-2)5-9(8)11/h3-5,11H,1-2H3
|
||||
| InChIKey |
UILPJVPSNHJFIK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 552-41-0
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SEG-1 | CVCL_8113 | Oesophageal cancer | Homo sapiens | ||
| Eca-109 | CVCL_6898 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Paeonol, in combination with cisplatin, had a significantly synergistic growth-inhibitory effect on oesophageal cell line, which may be related to apoptosis induction. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Protein kinase B alpha (AKT1) | Molecule Info | [3] | |
| Serine/threonine-protein kinase mTOR (mTOR) | Molecule Info | [3] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | cGMP-PKG signaling pathway | |||
| 6 | cAMP signaling pathway | |||
| 7 | Chemokine signaling pathway | |||
| 8 | HIF-1 signaling pathway | |||
| 9 | FoxO signaling pathway | |||
| 10 | Sphingolipid signaling pathway | |||
| 11 | mTOR signaling pathway | |||
| 12 | PI3K-Akt signaling pathway | |||
| 13 | AMPK signaling pathway | |||
| 14 | Apoptosis | |||
| 15 | Adrenergic signaling in cardiomyocytes | |||
| 16 | VEGF signaling pathway | |||
| 17 | Osteoclast differentiation | |||
| 18 | Focal adhesion | |||
| 19 | Tight junction | |||
| 20 | Signaling pathways regulating pluripotency of stem cells | |||
| 21 | Platelet activation | |||
| 22 | Toll-like receptor signaling pathway | |||
| 23 | Jak-STAT signaling pathway | |||
| 24 | T cell receptor signaling pathway | |||
| 25 | B cell receptor signaling pathway | |||
| 26 | Fc epsilon RI signaling pathway | |||
| 27 | Fc gamma R-mediated phagocytosis | |||
| 28 | TNF signaling pathway | |||
| 29 | Neurotrophin signaling pathway | |||
| 30 | Cholinergic synapse | |||
| 31 | Dopaminergic synapse | |||
| 32 | Insulin signaling pathway | |||
| 33 | Progesterone-mediated oocyte maturation | |||
| 34 | Estrogen signaling pathway | |||
| 35 | Prolactin signaling pathway | |||
| 36 | Thyroid hormone signaling pathway | |||
| 37 | Adipocytokine signaling pathway | |||
| 38 | Glucagon signaling pathway | |||
| 39 | Regulation of lipolysis in adipocytes | |||
| 40 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 41 | Carbohydrate digestion and absorption | |||
| 42 | Chagas disease (American trypanosomiasis) | |||
| 43 | Toxoplasmosis | |||
| 44 | Tuberculosis | |||
| 45 | Hepatitis C | |||
| 46 | Hepatitis B | |||
| 47 | Measles | |||
| 48 | Influenza A | |||
| 49 | HTLV-I infection | |||
| 50 | Epstein-Barr virus infection | |||
| 51 | Pathways in cancer | |||
| 52 | Proteoglycans in cancer | |||
| 53 | Colorectal cancer | |||
| 54 | Renal cell carcinoma | |||
| 55 | Pancreatic cancer | |||
| 56 | Endometrial cancer | |||
| 57 | Glioma | |||
| 58 | Prostate cancer | |||
| 59 | Melanoma | |||
| 60 | Chronic myeloid leukemia | |||
| 61 | Acute myeloid leukemia | |||
| 62 | Small cell lung cancer | |||
| 63 | Non-small cell lung cancer | |||
| 64 | Central carbon metabolism in cancer | |||
| 65 | Choline metabolism in cancer | |||
| 66 | Type II diabetes mellitus | |||
| 67 | MicroRNAs in cancer | |||
| NetPath Pathway | TSH Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | Apoptosis signaling pathway | |||
| 3 | EGF receptor signaling pathway | |||
| 4 | Endothelin signaling pathway | |||
| 5 | FGF signaling pathway | |||
| 6 | Huntington disease | |||
| 7 | Hypoxia response via HIF activation | |||
| 8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 9 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
| 10 | Interleukin signaling pathway | |||
| 11 | PI3 kinase pathway | |||
| 12 | T cell activation | |||
| 13 | VEGF signaling pathway | |||
| 14 | p53 pathway | |||
| 15 | Ras Pathway | |||
| 16 | p53 pathway by glucose deprivation | |||
| 17 | p53 pathway feedback loops 2 | |||
| 18 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| 3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| 4 | Insulin Signalling | |||
| 5 | Leucine Stimulation on Insulin Signaling | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Fc-epsilon receptor I signaling in mast cells | |||
| 3 | Endothelins | |||
| 4 | BCR signaling pathway | |||
| 5 | LPA receptor mediated events | |||
| 6 | Insulin Pathway | |||
| 7 | IL4-mediated signaling events | |||
| 8 | TCR signaling in naï | |||
| 9 | ||||
| 10 | Plasma membrane estrogen receptor signaling | |||
| 11 | CD40/CD40L signaling | |||
| 12 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 13 | Signaling events mediated by PTP1B | |||
| 14 | S1P3 pathway | |||
| 15 | Coregulation of Androgen receptor activity | |||
| 16 | Reelin signaling pathway | |||
| 17 | Integrin-linked kinase signaling | |||
| 18 | TCR signaling in naï | |||
| 19 | ||||
| 20 | Angiopoietin receptor Tie2-mediated signaling | |||
| 21 | FAS (CD95) signaling pathway | |||
| 22 | Thromboxane A2 receptor signaling | |||
| 23 | Regulation of Telomerase | |||
| 24 | FOXA2 and FOXA3 transcription factor networks | |||
| 25 | Glucocorticoid receptor regulatory network | |||
| 26 | mTOR signaling pathway | |||
| 27 | CXCR4-mediated signaling events | |||
| 28 | IGF1 pathway | |||
| 29 | FoxO family signaling | |||
| 30 | IL2 signaling events mediated by PI3K | |||
| 31 | Ceramide signaling pathway | |||
| 32 | p75(NTR)-mediated signaling | |||
| 33 | E-cadherin signaling in the nascent adherens junction | |||
| 34 | amb2 Integrin signaling | |||
| 35 | Integrins in angiogenesis | |||
| 36 | IFN-gamma pathway | |||
| 37 | ErbB1 downstream signaling | |||
| 38 | ErbB2/ErbB3 signaling events | |||
| 39 | IL6-mediated signaling events | |||
| 40 | E-cadherin signaling in keratinocytes | |||
| 41 | Nephrin/Neph1 signaling in the kidney podocyte | |||
| 42 | Retinoic acid receptors-mediated signaling | |||
| 43 | IL8- and CXCR2-mediated signaling events | |||
| 44 | Signaling events mediated by the Hedgehog family | |||
| 45 | Nongenotropic Androgen signaling | |||
| 46 | Hedgehog signaling events mediated by Gli proteins | |||
| 47 | Caspase Cascade in Apoptosis | |||
| 48 | CXCR3-mediated signaling events | |||
| 49 | VEGFR1 specific signals | |||
| 50 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 51 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 52 | a6b1 and a6b4 Integrin signaling | |||
| 53 | Aurora A signaling | |||
| 54 | Insulin-mediated glucose transport | |||
| 55 | Class I PI3K signaling events mediated by Akt | |||
| 56 | IL8- and CXCR1-mediated signaling events | |||
| 57 | HIF-1-alpha transcription factor network | |||
| 58 | p53 pathway | |||
| 59 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| 60 | VEGFR3 signaling in lymphatic endothelium | |||
| 61 | FGF signaling pathway | |||
| 62 | IL12-mediated signaling events | |||
| 63 | CDC42 signaling events | |||
| 64 | LKB1 signaling events | |||
| 65 | EGFR-dependent Endothelin signaling events | |||
| Reactome | Activation of BAD and translocation to mitochondria | Click to Show/Hide | ||
| 2 | GPVI-mediated activation cascade | |||
| 3 | PIP3 activates AKT signaling | |||
| 4 | Translocation of GLUT4 to the plasma membrane | |||
| 5 | Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||
| 6 | AKT phosphorylates targets in the cytosol | |||
| 7 | AKT phosphorylates targets in the nucleus | |||
| 8 | Negative regulation of the PI3K/AKT network | |||
| 9 | eNOS activation | |||
| 10 | AKT-mediated inactivation of FOXO1A | |||
| 11 | Integrin alphaIIb beta3 signaling | |||
| 12 | Deactivation of the beta-catenin transactivating complex | |||
| 13 | CD28 dependent PI3K/Akt signaling | |||
| 14 | CTLA4 inhibitory signaling | |||
| 15 | G beta:gamma signalling through PI3Kgamma | |||
| 16 | KSRP (KHSRP) binds and destabilizes mRNA | |||
| 17 | VEGFR2 mediated vascular permeability | |||
| 18 | TP53 Regulates Metabolic Genes | |||
| 19 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| 20 | Macroautophagy | |||
| 21 | mTORC1-mediated signalling | |||
| 22 | HSF1-dependent transactivation | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | DNA Damage Response (only ATM dependent) | |||
| 3 | TCR Signaling Pathway | |||
| 4 | Notch Signaling Pathway | |||
| 5 | EPO Receptor Signaling | |||
| 6 | IL-2 Signaling Pathway | |||
| 7 | Insulin Signaling | |||
| 8 | Endochondral Ossification | |||
| 9 | EGF/EGFR Signaling Pathway | |||
| 10 | IL-4 Signaling Pathway | |||
| 11 | TGF beta Signaling Pathway | |||
| 12 | IL-6 signaling pathway | |||
| 13 | Wnt Signaling Pathway Netpath | |||
| 14 | Copper homeostasis | |||
| 15 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 16 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 17 | IL-3 Signaling Pathway | |||
| 18 | Cardiac Hypertrophic Response | |||
| 19 | Translocation of GLUT4 to the Plasma Membrane | |||
| 20 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
| 21 | PIP3 activates AKT signaling | |||
| 22 | Signal Transduction of S1P Receptor | |||
| 23 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 24 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| 25 | Apoptosis | |||
| 26 | Alpha 6 Beta 4 signaling pathway | |||
| 27 | BDNF signaling pathway | |||
| 28 | Integrated Pancreatic Cancer Pathway | |||
| 29 | Oncostatin M Signaling Pathway | |||
| 30 | Corticotropin-releasing hormone | |||
| 31 | Interleukin-11 Signaling Pathway | |||
| 32 | AGE/RAGE pathway | |||
| 33 | TNF alpha Signaling Pathway | |||
| 34 | B Cell Receptor Signaling Pathway | |||
| 35 | Prostate Cancer | |||
| 36 | Signaling Pathways in Glioblastoma | |||
| 37 | TSLP Signaling Pathway | |||
| 38 | IL17 signaling pathway | |||
| 39 | IL-7 Signaling Pathway | |||
| 40 | Regulation of Microtubule Cytoskeleton | |||
| 41 | TWEAK Signaling Pathway | |||
| 42 | FSH signaling pathway | |||
| 43 | Leptin signaling pathway | |||
| 44 | TSH signaling pathway | |||
| 45 | RANKL/RANK Signaling Pathway | |||
| 46 | Integrated Breast Cancer Pathway | |||
| 47 | SREBP signalling | |||
| 48 | Integrated Cancer pathway | |||
| 49 | IL-1 signaling pathway | |||
| 50 | Metabolism of nitric oxide | |||
| 51 | Integrin-mediated Cell Adhesion | |||
| 52 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 53 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 54 | Angiogenesis | |||
| 55 | TOR Signaling | |||
| 56 | Regulation of toll-like receptor signaling pathway | |||
| 57 | AMPK Signaling | |||
| 58 | Androgen receptor signaling pathway | |||
| 59 | IL-5 Signaling Pathway | |||
| 60 | ErbB Signaling Pathway | |||
| 61 | Senescence and Autophagy in Cancer | |||
| 62 | Interferon type I signaling pathways | |||
| 63 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||
| 64 | Polycystic Kidney Disease Pathway | |||
| 65 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
| 66 | Signaling by Insulin receptor | |||
| 67 | Costimulation by the CD28 family | |||
| 68 | Type II diabetes mellitus | |||